![Claes Lundberg](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Dr. Claes Lundberg is Chief Executive Officer at Helicure AB.
Dr. Lundberg was previously employed as Senior Vice President-Research & Development by Resistentia Pharmaceuticals AB, a Principal by Innoventus Project AB, a Principal by Melacure Therapeutics AB, and a Principal by Pharmacia Corp.
He received his doctorate degree from the University of Uppsala.
Former positions of Claes Lundberg
Companies | Position | End |
---|---|---|
Resistentia Pharmaceuticals AB
![]() Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Chief Tech/Sci/R&D Officer | 23/06/2010 |
Helicure AB
![]() Helicure AB Pharmaceuticals: MajorHealth Technology Helicure AB develops and manufactures vaccines. It operates as a biotech company that focuses on developing vaccines for prevention of gastric cancer caused by Helicobacter pylori, through active immunisation in infected patients with persistent dyspepsia. The company was founded by Thomas Borén and Lennart Hammarström in 2005 and is headquartered in Umea, Sweden. | Chief Executive Officer | - |
Melacure Therapeutics AB
![]() Melacure Therapeutics AB Pharmaceuticals: MajorHealth Technology Melacure Therapeutics AB develops and manufactures pharmaceutical products. Its products are used for treatment of obesity, irritable bowel syndrome, inflammation, and sexual dysfunction. The company was founded in 1998 and is located in Uppsala, Sweden. | Corporate Officer/Principal | - |
Innoventus Project AB
![]() Innoventus Project AB Miscellaneous Commercial ServicesCommercial Services Innoventus Project AB engages in the development and commercialization of ideas, projects, and patents in life science. The company was founded on October 6, 2001 and is headquartered in Uppsala, Sweden. | Corporate Officer/Principal | - |
Pharmacia Corp.
![]() Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Corporate Officer/Principal | - |
Training of Claes Lundberg
University of Uppsala | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 5 |
---|---|
Resistentia Pharmaceuticals AB
![]() Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Health Technology |
Pharmacia Corp.
![]() Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
Innoventus Project AB
![]() Innoventus Project AB Miscellaneous Commercial ServicesCommercial Services Innoventus Project AB engages in the development and commercialization of ideas, projects, and patents in life science. The company was founded on October 6, 2001 and is headquartered in Uppsala, Sweden. | Commercial Services |
Melacure Therapeutics AB
![]() Melacure Therapeutics AB Pharmaceuticals: MajorHealth Technology Melacure Therapeutics AB develops and manufactures pharmaceutical products. Its products are used for treatment of obesity, irritable bowel syndrome, inflammation, and sexual dysfunction. The company was founded in 1998 and is located in Uppsala, Sweden. | Health Technology |
Helicure AB
![]() Helicure AB Pharmaceuticals: MajorHealth Technology Helicure AB develops and manufactures vaccines. It operates as a biotech company that focuses on developing vaccines for prevention of gastric cancer caused by Helicobacter pylori, through active immunisation in infected patients with persistent dyspepsia. The company was founded by Thomas Borén and Lennart Hammarström in 2005 and is headquartered in Umea, Sweden. | Health Technology |
- Stock Market
- Insiders
- Claes Lundberg